Correction to: Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab
Hepatol Int. 2023 Feb;17(1):271-273.
doi: 10.1007/s12072-022-10446-0.
Epub 2022 Nov 16.